Companies · Pharmaceuticals

Metabolic Solutions Development Co Llc

KALAMAZOO · Pharmaceuticals

Diligence memoA one-page analyst read on Metabolic Solutions Development Co Llc — recommendation, valuation, rhythm, risks.
$50.1M
Total raised · real
5
Rounds
0.1×
Latest step-up
Top 20%
Sector rank · raised
Series B
Latest stage · inferred · Wed Jan 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Metabolic Solutions Development Co Llc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.01× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.4 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Metabolic Solutions Development Co Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
17.0 yr record
Peak capital year was 2012 with $30.4M across 3 filings.
Market position
ahead of 81% of Pharmaceuticals peers
Capital scale is ahead of 81% of Pharmaceuticals peers; modeled value is above 11% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2012: $30.4M across 3 filings.
  • Largest single filing was $16.1M on 2012-08-09.
  • Filing rows sum to $64.4M, while canonical raised total is $50.1M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Metabolic Solutions Development Co Llc is one of 1613 Pharmaceuticals companies tracked from KALAMAZOO. By capital raised it ranks in the upper tier (ahead of 81% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
15
Investors (latest)
2019-01-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2009-07-01 Raised $12M (real) Modeled valuation $372M (est)Series A2009Series A · 2010-09-27 Raised $15M (real) Modeled valuation $464M (est)Series A2010Series A · 2011-07-29 Raised $6.8M (real) Modeled valuation $211M (est)Series A2011Series B · 2012-08-09 Raised $16M (real) Modeled valuation $549M (est)Series B2012Series A · 2012-08-09 Raised $12M (real) Modeled valuation $365M (est)Series A2012Seed · 2012-08-09 Raised $2.5M (real) Modeled valuation $95M (est)Seed2012Series B · 2019-01-30 Raised $200K (real) Modeled valuation $6.8M (est)Series B2019+$15M+$6.8M+$16M+$12M+$2.5M+$200KCumulative $64M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$12.0M · 2009
Series A extension$15.0M · 2010
Series A extension$6.8M · 2011
Series B$16.1M · 2012
Bridge · Series B-stage$11.8M · 2012smaller follow-on
Bridge · Series B-stage$2.5M · 2012smaller follow-on
Series B extension$200K · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$6.8M
Base estimate est.
$420K
Conservative case
$26.2M
Upside case
$1.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $371.7M · 2009-07-012009Series A · modeled $464.0M · 2010-09-27Series A · modeled $210.9M · 2011-07-29Series B · modeled $548.7M · 2012-08-09Series A · modeled $364.9M · 2012-08-09Seed · modeled $95.1M · 2012-08-09Series B · modeled $6.8M · 2019-01-302019
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
57%
Survival probability
38% low · 70% high
1.49×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
7.4 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$5.2M/yr
Capital velocity
17.0 yr
On record since
2009
First round
7
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 6.2× above median
This company$50.1M
Sector median$8.1M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.0× of median
This company$200K
Sector median$18.0M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$6.8M
Sector median$76.1M

Raised more than 81% of sector peers (real $). Modeled value above 11% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #60 of 61.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Evolus, Inc. · Series B Raised $40.5M · modeled $1.4B (est)HOOKIPA Pharma Inc. · Series B Raised $37.4M · modeled $1.3B (est)ESSA Pharma Inc. · Series B Raised $56.0M · modeled $1.2B (est)Pieris Pharmaceuticals, Inc. · Series B Raised $102.1M · modeled $1.1B (est)Amylyx Pharmaceuticals, Inc. · Series B Raised $65.1M · modeled $1.0B (est)PassPort Technologies, Inc. · Series B Raised $30.0M · modeled $1.0B (est)Savara Inc · Series B Raised $30.9M · modeled $910.6M (est)InCarda Therapeutics, Inc. · Series B Raised $66.3M · modeled $857.5M (est)Aceto Management, L.L.C. · Series B Raised $23.6M · modeled $803.2M (est)GPI Finco (Canada) Inc. · Series B Raised $22.9M · modeled $778.0M (est)Phosplatin Therapeutics LLC · Series B Raised $72.3M · modeled $722.8M (est)Lannett Co Inc · Series B Raised $28.0M · modeled $691.3M (est)Metabolic Solutions Development Co Llc (this company) Raised $50.1M · modeled $6.8M (est)Metabolic Solutions Development Co Llc
CompanyStageRaised · realValue · estvs peer med.
Evolus, Inc.Series B$40.5M$1.4B2.74×
HOOKIPA Pharma Inc.Series B$37.4M$1.3B2.57×
ESSA Pharma Inc.Series B$56.0M$1.2B2.47×
Pieris Pharmaceuticals, Inc.Series B$102.1M$1.1B2.20×
Amylyx Pharmaceuticals, Inc.Series B$65.1M$1.0B2.06×
PassPort Technologies, Inc.Series B$30.0M$1.0B2.06×
Savara IncSeries B$30.9M$910.6M1.84×
InCarda Therapeutics, Inc.Series B$66.3M$857.5M1.73×
Aceto Management, L.L.C.Series B$23.6M$803.2M1.62×
GPI Finco (Canada) Inc.Series B$22.9M$778.0M1.57×
Phosplatin Therapeutics LLCSeries B$72.3M$722.8M1.46×
Lannett Co IncSeries B$28.0M$691.3M1.40×
Metabolic Solutions Development Co Llc this companySeries B$50.1M$6.8M0.01×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$12.0M2009-07-01$54.5M$371.7M85%
Series A$15.0M2010-09-27$68.1M$464.0M85%
Series A$6.8M2011-07-29$31.0M$210.9M85%
Series B$16.1M2012-08-09$89.6M$548.7M85%
Series A$11.8M2012-08-09$53.6M$364.9M85%
Seed$2.5M2012-08-09$12.5M$95.1M85%
Series B$200K2019-01-30$1.1M$6.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$12.0M2009-07-01
    • First recorded raise — entered as Series A.
  2. Series A$15.0M2010-09-27
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 24 investors on this round.
  3. Series A$6.8M2011-07-29
    • Raised 10 mo later, in step with the ~13 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
    • 23 investors on this round.
  4. Series B$16.1M2012-08-09
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 30 investors on this round.
  5. Series A$11.8M2012-08-09
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 23 investors on this round.
  6. Seed$2.5M2012-08-09
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.7× smaller than the prior — bridge or down round.
    • Switched to Rule 06 (was Rule 506(b)).
    • 1 investor on this round.
  7. Series B$200K2019-01-30
    • Raised again after 78 mo — slower than the ~13 mo sector norm.
    • Round 12.5× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 15 investors on this round.
Intelligence
2020 ~Q3
Modeled next raise · ~19mo cadence
$200K
Modeled next size est.range $200K$320K
0.1×
Last step-up
$5.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Zerbe4 other2012-08
Mark Olesnavage3 other2009-07
Gerald Callahan2 other2009-07
Jim Schultz2 other2012-08
Michael Jandernoa1 other2010-09
Stephen Benoit1 other2011-07
William Parfet1 other2010-09
Angeline Shashlo2010-09
Gerard Colca2010-09
Gerard R. Colca2009-07
James VanderLugt2010-09
John Landis2010-09
Rolf F. Kletzien2009-07
Rolf Kletzien2010-09
Sandi Doctor2019-01
Registry & provenance

Metabolic Solutions Development Co Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1422580
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cirius Therapeutics, Inc.BiotechnologySeries B$49.6M$3.3Mnetwork3 shared operators · same stage
TFF Pharmaceuticals, Inc.PharmaceuticalsSeries B$49.4M$9.2Msame sector · same stage
Limerick Biopharma IncPharmaceuticalsSeries B$52.8M$16.3Msame sector · same stage
Humanigen, IncPharmaceuticalsSeries B$39.2M$16.8Msame sector · same stage
Indaptus Therapeutics, Inc.PharmaceuticalsSeries B$35.0M$11.1Msame sector · same stage
Variant Pharmaceuticals, Inc.PharmaceuticalsSeries B$33.1M$7.2Msame sector · same stage
EPALEX CorpPharmaceuticalsSeries B$30.8M$5.0Msame sector · same stage
Emmaus Life Sciences, Inc.PharmaceuticalsSeries B$102.9M$2.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Metabolics Pharma, Inc.BiotechnologySeries A$26.6M84%
Capitol Wellness Solutions LLCPharmaceuticalsSeed$76.1M81%
EnzymeBioSystemsPharmaceuticalsPre-Seed$18.4M81%
IntelGenx Technologies Corp.PharmaceuticalsSeed$7.1M80%
Chemical Solutions Group, LLCBiotechnologySeries A$361.5M80%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B79%
Stream Biomedical, Inc.PharmaceuticalsSeries B$412.2M79%
GT Metabolic Solutions IncOtherSeries B$168.7M79%
Frequently asked
How much funding has Metabolic Solutions Development Co Llc raised?
Metabolic Solutions Development Co Llc has raised approximately $50.1M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Metabolic Solutions Development Co Llc's estimated valuation?
Provath's modeled valuation for Metabolic Solutions Development Co Llc is approximately $6.8M (modeled range $420K–$26.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Metabolic Solutions Development Co Llc at?
Metabolic Solutions Development Co Llc's latest modeled financing stage is Series B. Its most recent recorded round closed around Wed Jan 30.
What does Metabolic Solutions Development Co Llc do and where is it based?
Metabolic Solutions Development Co Llc operates in the Pharmaceuticals sector, based in KALAMAZOO.
Explore related

See where Metabolic Solutions Development Co Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Metabolic Solutions Development Co Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.